European Union - English - EMA (European Medicines Agency)

virbac s.a. - leishmania infantum excreted secreted proteins - immunologicals - dogs - for the active immunisation of leishmania-negative dogs from six months of age to reduce the risk to develop an active infection and clinical disease after contact with leishmania infantum.the efficacy of the vaccine has been demonstrated in dogs submitted to multiple natural parasite exposure in zones with high infection pressure.onset of immunity: 4 weeks after the primary vaccination course.duration of immunity: 1 year after the last re-vaccination.

European Union - English - EMA (European Medicines Agency)

leti pharma, s.l.u. - recombinant protein q from leishmania infantum mon-1 - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - dogs - for active immunisation of dogs from 6 months of age to reduce the risk of developing a clinical case of leishmaniasis.

United Kingdom - English - VMD (Veterinary Medicines Directorate)

virbac - leishmania infantum excreted secreted proteins - lyophilisate for suspension for injection - inactivated parasitic vaccine - dogs

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: hydrogenated soy phosphatidylcholine; sucrose; dl-alpha-tocopherol; distearoylphosphatidylglycerol; sodium succinate; cholesterol - indications: ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum. indicated as at 8 september 2003 :ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pentamidine isetionate, quantity: 300 mg - injection, powder for - excipient ingredients: - pentamidine isethionate is indicated for intravenous administration in the treatment of the following conditions: . as an alternative first line treatment for pneumocystis carinii infection in aids patients; . as second line treatment for pneumocystis carinii infection in non-aids patients; . as second line treatment of leishmaniasis (visceral and cutaneous), except leishmania aethiopica where it may be used as first line treatment; . as second line treatment for trypanosomiasis (except for the trypanosomiasis rhodesiense strain due to lack of efficacy).

United Kingdom - English - VMD (Veterinary Medicines Directorate)

leti pharma, s.l.u. - recombinant protein q from leishmania infantum mon-1 - lyophilisate and solvent for solution for injection - inactivated parasitic vaccine - dogs

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - sodium stibogluconate - solution for injection - sodium stibogluconate 10 g / 100 ml - sodium stibogluconate - sodium stibogluconate - pentostam is indicated for the following diseases: visceral leishmaniasis (kala azar).cutaneous leishmaniasis.south american mucocutaneous leishmaniasis.pentostam may also be of value in the treatment of leishmaniasis recidivans and diffuse cutaneous leishmaniasis in the new world.

Israel - English - Ministry of Health

megapharm ltd - miltefosine - hard capsule - miltefosine 10 mg - miltefosine - -treatment of visceral leishmaniasis caused by leishmania donovani. -treatment of cutaneous leishmaniasis caused by leishmania brasiliensis complex or leishmania mexicana complex.

Israel - English - Ministry of Health

megapharm ltd - miltefosine - hard capsule - miltefosine 50 mg - miltefosine - -treatment of visceral leishmaniasis caused by leishmania donovani. -treatment of cutaneous leishmaniasis caused by leishmania brasiliensis complex or leishmania mexicana complex.

New Zealand - English - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - amphotericin b 50mg - powder for injection - 50 mg - active: amphotericin b 50mg excipient: cholesterol hydrochloric acid alpha-tocopherol distearoylphosphatidylglycerol phosphatidylcholines, soya, hydrogenated phosphatidylglycerols as sodium salt sodium hydroxide sodium succinate sucrose - ambisome is indicated for: · prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for · the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b. ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.